Skip to main content
NPJ Digital Medicine logoLink to NPJ Digital Medicine
. 2023 Feb 22;6:27. doi: 10.1038/s41746-023-00769-z

Author Correction: Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials

Andre Esteva 1,, Jean Feng 2, Douwe van der Wal 1, Shih-Cheng Huang 3, Jeffry P Simko 4, Sandy DeVries 5, Emmalyn Chen 1, Edward M Schaeffer 6, Todd M Morgan 7, Yilun Sun 8, Amirata Ghorbani 9, Nikhil Naik 9, Dhruv Nathawani 9, Richard Socher 9, Jeff M Michalski 10, Mack Roach III 4, Thomas M Pisansky 11, Jedidiah M Monson 12, Farah Naz 13, James Wallace 14, Michelle J Ferguson 15, Jean-Paul Bahary 16, James Zou 3, Matthew Lungren 3, Serena Yeung 3, Ashley E Ross 6; NRG Prostate Cancer AI Consortium, Howard M Sandler 17, Phuoc T Tran 18, Daniel E Spratt 19, Stephanie Pugh 20, Felix Y Feng 4,#, Osama Mohamad 4,#
PMCID: PMC9947124  PMID: 36813827

Correction to: npj Digital Medicine 10.1038/s41746-022-00613-w, published online 08 June 2022

The original version of the published Article contained an error in the description of the prostate tissue samples in the Methods and Results sections, which stated that “pretreatment biopsy samples” and “pretreatment prostate biopsies” were used in this study. Both instances have been updated to “pretreatment and posttreatment prostate tissue”, and these changes are reflected in the HTML and PDF versions of the Article. Furthermore, we have added descriptions of the use of posttreatment prostate tissue during model development throughout the Article.

In the interest of transparency and clinical relevance, we repeated the evaluation of model performance in the validation set after removing any cases with post-treatment prostate tissue. This results in a slightly smaller cohort (n = 931) for validation, compared to the 20% validation set used in the original paper, and still demonstrates similar performance to the MMAI algorithms using only pretreatment tissue for each clinical endpoint. Table 2 has been added to the HTML and PDF versions of the Article.

Table 2.

Validation results for the subset of patients from the 20% validation set reported in the Article that includes patients with pretreatment slides only (n = 931).

Clinical outcome NCCN AUC estimates (95% CI) MMAI AUC (95% CI) Differential AUC estimate
(MMAI - NCCN)
Comparative test p value
Distant metastasis (5-year) 0.72 (0.67–0.78) 0.83 (0.78–0.88) 0.11 <0.001
Distant metastasis (10-year) 0.69 (0.64–0.74) 0.78 (0.73–0.84) 0.09 <0.001
Biochemical failure (5-year) 0.61 (0.57–0.64) 0.69 (0.65–0.73) 0.08 <0.001
Biochemical failure (10-year) 0.62 (0.58–0.66) 0.68 (0.63–0.72) 0.06 0.004
Prostate cancer-specific survival (10-year) 0.67 (0.61–0.73) 0.77 (0.70–0.83) 0.10 <0.001
Overall survival (10-year) 0.57 (0.54–0.61) 0.65 (0.61–0.69) 0.08 <0.001

The subcohort represented in this table is smaller than reported in the Article (n = 1109).

AUC area under the curve, CI confidence interval, MMAI multimodal artificial intelligence, NCCN National Comprehensive Cancer Network.

Data availability

The data availability statement has also been updated in the PDF and HTML versions of the Article to read, “The data published in this article will be publicly available six months from publication, through requests made to NRG Oncology at APC@nrgoncology.org”.

Footnotes

These authors contributed equally: Felix Y. Feng, Osama Mohamad.

A list of authors and their affiliations appears online.

Contributor Information

Andre Esteva, Email: aesteva@artera.ai.

NRG Prostate Cancer AI Consortium:

Michael Kucharczyk, Luis Souhami, Leslie Ballas, Christopher A. Peters, Sandy Liu, Alexander G. Balogh, Pamela D. Randolph-Jackson, David L. Schwartz, Michael R. Girvigian, Naoyuki G. Saito, Adam Raben, Rachel A. Rabinovitch, and Khalil Katato

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The data availability statement has also been updated in the PDF and HTML versions of the Article to read, “The data published in this article will be publicly available six months from publication, through requests made to NRG Oncology at APC@nrgoncology.org”.


Articles from NPJ Digital Medicine are provided here courtesy of Nature Publishing Group

RESOURCES